Innovations in Drug Delivery, Cancer Immunotherapies, Biomarker Identification, and Gene Therapy for Preventing Vision Loss

Innovations in Drug Delivery, Cancer Immunotherapies, Biomarker Identification, and Gene Therapy for Preventing Vision Loss

RELEASE DATE
31-Aug-2018
REGION
Global
Research Code: D758-00-89-00-00
SKU: HC03087-GL-TA_22388

$250.00

Special Price $187.50 save 25 %

In stock
SKU
HC03087-GL-TA_22388

$250.00

$187.50 save 25 %

DownloadLink

Pay by invoice

ENQUIRE NOW

Description

This Genetic Technology TOE depicts life sciences trends across drug delivery platforms, cancer immunotherapies, biomarker identification, and gene therapy. Among the therapeutic areas in focus, age-related macular degeneration (AMD), aggressive childhood cancers, and bladder cancer, are of note. Clinical trial analysis of recombinant drugs for different forms of cancer is also presented.

The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants.

The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.

Keywords: Drug delivery, cancer immunotherapies, biomarker identification, gene therapy, vision loss, age-related macular degeneration, aggressive childhood cancers, bladder cancer

Table of Contents

Recent Advancements in Development of Novel Drug Delivery Systems, Immunotherapies for Pediatric Cancers, Biomarker identification for Bladder Cancer, and Gene Therapy for preventing Vision loss

  • Advancements in Mode of Drug Delivery for Age-related Macular Degeneration
  • Immunotherapy Developments for Aggressive Childhood Cancers
  • Novel Biomarkers for p53-like Subtype of Bladder Cancer
  • Novel Gene Therapy Construct that Halts Vision Loss

Clinical Trial Analysis and Key Contacts

  • Clinical Trial Analysis of Recombinant Drugs for Different Forms of Cancer
  • Key Contacts
Related Research
This Genetic Technology TOE depicts life sciences trends across drug delivery platforms, cancer immunotherapies, biomarker identification, and gene therapy. Among the therapeutic areas in focus, age-related macular degeneration (AMD), aggressive childhood cancers, and bladder cancer, are of note. Clinical trial analysis of recombinant drugs for different forms of cancer is also presented. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Drug delivery, cancer immunotherapies, biomarker identification, gene therapy, vision loss, age-related macular degeneration, aggressive childhood cancers, bladder cancer
More Information
No Index No
Podcast No
Industries Healthcare
WIP Number D758-00-89-00-00
Is Prebook No
Ti Codes D753,D904,D913,D91A,D91B,D932,D933,D935